We report the development of a previously undescribed gold nanoparticle bio-barcode
assay probe for the detection of prostate specific antigen (PSA) at 330 fg/mL, automation of
the assay, and the results of a clinical pilot study designed to assess the ability of the assay
to detect PSA in the serum of 18 men who have undergone radical prostatectomy for
prostate cancer. Due to a lack of sensitivity, available PSA immunoassays are often not
capable of detecting PSA in the serum of men after radical prostatectomy. This new bio …

84.1 Introduction o adjuvant or salvage therapies. malignancy among is cancer aa death in
the American United Stat men es [1]. and Pr is ostat the e-specific second leading antigen
cause (PSA) of epithelial pr serum oduct biomar of the ker ph used ysiology for CaP
screening and is near exclusively clinical low cells er limits [2]. Commer of detection cially
and available pathoph PSA ysiology immunoassa of pr y ostatic s, with accur screening
purposes [3]. ately quantify PSA serum lev do els wn within to 0.1 the ng range PSA/mL …